Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PDE2A | O00408 | 4/20 | 0.46 |
| ▸ | METAP2 | P50579 | 2/20 | 0.43 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 6/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17204363 | 0.98 | ALDH1A1 (0.46) | ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL1333149 | 0.86 | LMNA (0.44) | ALDH1A1KDM4EHPGDSMN1; SMN2PDE2A | |
| SCHEMBL14956499 | 0.82 | METAP2 (0.45) | ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL1331960 | 0.74 | GAA (0.45) | ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL1333582 | 0.74 | METAP2 (0.52) | ALDH1A1KDM4EHPGDSMN1; SMN2PDE2A | |
| SCHEMBL1333583 | 0.74 | METAP2 (0.52) | ALDH1A1KDM4EPDE2AMETAP2GAA | |
| SCHEMBL1236763 | 0.73 | AKT1 (0.46) | ALDH1A1KDM4EGAAGLAEGLN2 | |
| SCHEMBL1333145 | 0.72 | METAP2 (0.58) | PDE2AMETAP2EGLN2PDE3BPDE3A | |
| SCHEMBL1237759 | 0.71 | AKT1 (0.45) | ALDH1A1KDM4EGAAGLAEGLN2 | |
| SCHEMBL1331466 | 0.70 | ALDH1A1 (0.45) | ALDH1A1KDM4EHPGDSMN1; SMN2METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230225996-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | SYNDEVRX, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230225996-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | METAP2, METAP1, PEBP1 | ALDH1A1 3316/4885KDM4E 3981/4885HPGD 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.